COMBINED THERAPY WITH CAPTOPRIL AND POTASSIUM SUPPLEMENTATION - A POTENTIAL FOR HYPERKALEMIA
COMBINED THERAPY WITH CAPTOPRIL AND POTASSIUM SUPPLEMENTATION - A POTENTIAL FOR HYPERKALEMIA
复制标题
DOI：
10.1001/archinte.144.12.2371
复制
发表时间：
1984-01-01
影响因子：
--
通讯作者：
MIODUCH, HJ
中科院分区：
文献类型：
--
作者：
BURNAKIS, TG;MIODUCH, HJ
卡托普利 (Capoten) 是一种血管紧张素转换酶抑制剂，越来越多地用于治疗高血压和充血性心力衰竭。许多患有这些疾病的患者都接受包括保钾利尿剂或钾补充剂的治疗方案。在对 5 名此类患者的监测中，一旦在治疗中添加卡托普利，就会发现血清 K 水平显着升高（3.88.+-.0.41 至 4.84.+-.0.45 meq/l）。其中 3 名患者出现实验室诊断的高钾血症。血清 K 水平保持升高，直至 K 补充剂或卡托普利治疗减少或停止。卡托普利和钾补充剂或保钾利尿剂的组合代表了潜在的重要药物相互作用。使用这些药物组合时，应密切监测患者是否可能出现高钾血症。
Captopril (Capoten), an angiotensin-converting enzyme inhibitor, is being used increasingly in the treatment of both hypertension and congestive heart failure. Many of the patients with these disease states have treatment regimens including K-sparing diuretics or K supplements. In monitoring of 5 such patients, a significant increase in serum K level (3.88 .+-. 0.41 to 4.84 .+-. 0.45 meq/l) was noted once captopril was added to their therapy. Laboratory-diagnosed hyperkalemia occurred in 3 of these patients. Serum K levels remained elevated until K supplementation or captopril therapy was reduced or discontinued. The combination of captopril and K supplements or K-sparing diuretics represents a potentially important drug interaction. Patients should be closely monitored for possible hyperkalemia when using these drug combinations.